High-Level Results From DESTINY-Breast11 Phase III Trial for High-Risk HER2-Positive Early-stage Breast Cancer
Mohit Manrao, SVP, Head of US Oncology at AstraZeneca, shared a post on LinkedIn:
“This post is intended for a US audience.
Today, AstraZeneca and Daiichi Sankyo announced high-level results from DESTINY-Breast11, which evaluated our HER2-directed therapy in patients with high-risk HER2-positive early-stage breast cancer in the neoadjuvant setting. Notably, these results are the first for our therapy in early-stage breast cancer.
The existing standard of care typically involves a combination of chemotherapies, which can be challenging to tolerate. Currently, only about half of patients achieve a pathologic complete response – meaning no evidence of invasive cancer cells in the breast and lymph nodes – following neoadjuvant treatment and surgery. More progress is needed for people living with high-risk early breast cancer.
That’s why we’re focused on developing new treatment options in this setting, where the goal is to cure. With an ambition to eliminate cancer as a cause of death, I’m proud of the advances we’re making.
Read more about the results.”
More posts featured Mohit Manrao.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023